List view / Grid view
Analysis cites personalised medicine, outsourcing and digitalisation as some of the key factors set to advance the pharmaceutical analytical testing market to 2032.
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
A lack of standardised testing methods and subsequent delayed product approvals is limiting growth of the pyrogen testing market, according to a report.
The biopharma industry will see more customisation in the design of bioprocess containers in the next five years, a market report has predicted.
Digitalisation is a driving factor for the global process analytical technology (PAT) market, according to a report.
Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, states a new report.
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
Research suggests rising demand for lab automation will help promote the growth of the laboratory information management system (LIMS) market.
Growth in the global transfection technologies market will be driven by emerging methods and the increasing prevalence of chronic diseases over the next five years.
The global cell and gene therapy manufacturing services market is expected to grow at a CAGR of 12.4 percent in the next five years.
New report suggests the cell line development services market will witness a 14.3 percent CAGR between 2021 and 2030.
Market research shows increasing pharmaceutical R&D investment and advances in quality control (QC) technologies will drive pharmaceutical QC market growth.
Market analysts suggest COVID-19 and the rising prevalence of chronic disease will both contribute to growth in the global clinical trials market.
Research suggests the development of new instruments and growing government investments, particularly in Germany, will drive growth of the European molecular spectroscopy market.
With roughly a fifth of the mass spectrometry market made up by pharma and biotech, growing R&D investment and technological breakthroughs in mass spectrometers will contribute to market growth.
